Trial Profile
Quantitative diffusion-weighted MR imaging of microcapillary perfusion and tissue diffusivity as biomarkers of response of renal cell carcinoma to treatment with sunitinib
Status:
Not stated
Phase of Trial:
Phase IV
Latest Information Update: 19 Jul 2011
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Biomarker; Pharmacodynamics
- 19 Jul 2011 New trial record